Literature DB >> 27504553

Retinal Thickness and Visual Acuity in Diabetic Macular Edema: An Optical Coherence Tomography-Based Study.

Farrah Islam1.   

Abstract

OBJECTIVE: To determine the relationship between foveal (retinal) thickness and visual acuity in diabetic macular edema through optical coherence tomography (OCT) mapping software. STUDY
DESIGN: Cross-sectional descriptive study. PLACE AND DURATION OF STUDY: The Retina Clinic of Al-Shifa Trust Eye Hospital, Rawalpindi, from August 2011 to August 2012.
METHODOLOGY: Eighty eyes of 68 patients with clinical diagnosis of diabetic macular edema, based on complete ophthalmic examination, were enrolled. The best-corrected visual acuity was recorded on logMar scale. OCTimaging was performed through dilated pupil by experienced operator. Foveal thickness was determined. OCTparameters of macular thickness were analysed with baseline variables including age, duration since diagnosed with diabetes, and visual acuity.
RESULTS: The mean visual acuity was 0.81 (0.2 - 1.8) logMar units. The average foveal thickness was 395.09 ±142.26 (183 - 825 µm). There was moderate correlation between foveal thickness and visual acuity (rs= 0.574, p < 0.001), absent in those who had visual acuity worse than 1 logMar. There was a weak positive association between foveal thickness and the duration of diabetes (rs=0.249, p < 0.05). There was, however, no correlation between foveal thickness and age (rs= 0.012, p=0.919).
CONCLUSION: There is a moderate correlation between visual acuity and degree of foveal thickening in diabetic macular edema, hence two cannot be used interchangeably in clinical practice.

Entities:  

Mesh:

Year:  2016        PMID: 27504553     DOI: 2379

Source DB:  PubMed          Journal:  J Coll Physicians Surg Pak        ISSN: 1022-386X            Impact factor:   0.711


  2 in total

1.  Intravitreal ranibizumab alone or in combination with panretinal photocoagulation for the treatment of proliferative diabetic retinopathy with coexistent macular edema: long-term outcomes of a prospective study.

Authors:  Irini Chatziralli; Eleni Dimitriou; George Theodossiadis; Dimitrios Kazantzis; Panagiotis Theodossiadis
Journal:  Acta Diabetol       Date:  2020-05-29       Impact factor: 4.280

2.  Fluctuations in macular thickness in patients with diabetic macular oedema treated with anti-vascular endothelial growth factor agents.

Authors:  Victoria Y Wang; Blanche L Kuo; Andrew X Chen; Kevin Wang; Tyler E Greenlee; Thais F Conti; Rishi P Singh
Journal:  Eye (Lond)       Date:  2021-07-07       Impact factor: 4.456

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.